Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.

about

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.

Item

http://www.wikidata.org/entity/Q50181358

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.

@en

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.

@nl

type

Item

label

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.

@en

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.

@nl

prefLabel

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.

@en

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.

@nl

P1476

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.

@en

P2093

Bülent Karabulut

http://www.w3.org/2001/XMLSchema#string

Devrim Çabuk

http://www.w3.org/2001/XMLSchema#string

Faysal Dane

http://www.w3.org/2001/XMLSchema#string

Hasan Şenol Coşkun

http://www.w3.org/2001/XMLSchema#string

Hatice Doruk

http://www.w3.org/2001/XMLSchema#string

Levent Korkmaz

http://www.w3.org/2001/XMLSchema#string

Mustafa Karaağaç

http://www.w3.org/2001/XMLSchema#string

Nazım Serdar Turhal

http://www.w3.org/2001/XMLSchema#string

Nilüfer Avcı

http://www.w3.org/2001/XMLSchema#string

Nuri Faruk Aykan

http://www.w3.org/2001/XMLSchema#string

P2860

Obesity in cancer survival

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study.

Primary prevention of colorectal cancer.

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

Angiogenesis modulates adipogenesis and obesity.

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.

Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents.

P2888

s12029-017-0047-2

P304

214-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12029-017-0047-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mehmet Artac

P577

2018-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29302856

http://www.w3.org/2001/XMLSchema#string

P921

Adipositas

colorectal cancer